Nurix Therapeutics, Inc. (NRIX)

Pharmaceutical Preparations · market cap $2.6B · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-08 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Nurix Therapeutics (NRIX) is a clinical-stage pharmaceutical company with 286 employees and a ~$2.5B market cap, whose lead asset NX-5948 is in Phase 2 development for Chronic Lymphocytic Leukemia (CLL). The company carries only $71.2M in cash against a reported 3-month runway, creating acute near-term financing risk despite a consensus strong-buy rating from 16 analysts.

The catalyst path

2026-10-08 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
NX-5948	Phase 2	Chronic Lymphocytic Leukemia (CLL)

Price & technical context

3-month

-0.8%

6-month

+53.0%

12-month

+155.5%

52-wk range

$9.08–$27.79

vs 50-day MA

-6.3%

vs 200-day MA

+21.3%

Realized vol

57.8%

Max drawdown

-70.7%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for NRIX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.